Gossamer Bio vs Verastem
GOSS and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GOSS and VSTM compare
Verastem is the larger company, worth 11 times as much as Gossamer Bio ($741M against $67.1M).
Gossamer Bio keeps more of each dollar of sales as profit, with a net margin of −159% compared with −178% at Verastem.
Verastem scores higher on the StockData Score (3 against 2 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GOSS | VSTM |
|---|---|---|
| Size and price | ||
| Market cap | $67.1M | $741M |
| Share price | $10.97 | $8.18 |
| Change, 1 year | −94.9% | −3.9% |
| Change, 5 years | −98.8% | −77.0% |
| Beta (5Y) | 1.58 | 1.37 |
| Employees | 161 | 102 |
| StockData Score | ||
| Total score | 2 | 3 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.9× (better) | 7.4× |
| P/B | – | 73.3× |
| FCF yield | −233% | – |
| Growth | ||
| Revenue growth (TTM) | 78.0% | – |
| Revenue growth, 5Y average | – | −19.0% |
| Profitability | ||
| Operating margin | −140% (better) | −194% |
| Net margin | −159% (better) | −178% |
| FCF margin | −199% | – |
| Financial health | ||
| Interest coverage | −10.3× (better) | −141.9× |
| Current ratio | 0.60 | 1.93 (better) |
| Altman Z-score | −37.94 | −7.82 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 78.0% | 109% |
| Held by insiders | – | 1.8% |
| Insider net buying, 12 months | – | −$816K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 22.1% |
Go deeper
- GOSS stock overview
- GOSS income statement
- GOSS valuation and score
- VSTM stock overview
- VSTM income statement
- VSTM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.